. Author manuscript; available in PMC: 2021 Apr 1.

Published in final edited form as: Surg Oncol Clin N Am. 2020 Apr;29(2):165–183. doi: 10.1016/j.soc.2019.10.002

Table 5.

Indicated imaging by disease site

NET Location	Recommended imaging
Gastric Type 1, 2, 3	Recommend EGD in Types 1–3; consider EUS (for infiltration, nodal assessment); CT or MR staging with Type 3; consider ⁶⁸Ga-DOTATATE PET for Types 2 and 3
Duodenal	Recommend EGD; consider EUS (for infiltration, nodal assessment); recommend CT or MR abdomen for staging; consider ⁶⁸Ga-DOTATATE PET
Jejuno-Ileal, Appendix, Cecum	Recommend CT or MR abdomen/pelvis; consider specific enterography or enteroscopy protocols for jejuno-ileal or colonoscopy for cecal; recommend ⁶⁸Ga-DOTATATE PET for staging; consider echocardiogram
Distal Colo-Rectal	Recommend CT or MR abdomen/pelvis; recommend colonoscopy; consider EUS for rectal lesions; recommend ⁶⁸Ga-DOTATATE PET
Pancreatic	Recommend CT or MR for staging; consider EGD / EUS for staging / biopsy; recommend ⁶⁸Ga-DOTATATE PET for staging
Poorly differentiated NE carcinoma (NEC)	Recommend CT chest/abdomen/pelvis; Consider ¹⁸FDG-PET, ⁶⁸Ga-DOTATATE PET, Nuclear bone scan

EGD: esophagogastroduodenoscopy.

Data from Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557–577.